Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | NFE2L2 | Q16236 | 5/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | CA12 | O43570 | 3/20 | 0.34 |
| ▸ | CA1 | P00915 | 3/20 | 0.34 |
| ▸ | CA2 | P00918 | 3/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.34 |
| ▸ | CA7 | P43166 | 2/20 | 0.34 |
| ▸ | CA9 | Q16790 | 2/20 | 0.34 |
| ▸ | CA4 | P22748 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1884282 | 0.77 | SMN1; SMN2 (0.44) | SMN1; SMN2NFE2L2NPC1PRMT1GAA | |
| SCHEMBL31438691 | 0.76 | SMN1; SMN2 (0.47) | SMN1; SMN2NFE2L2PRMT1MAPTLMNA | |
| SCHEMBL8417921 | 0.76 | SMN1; SMN2 (0.47) | SMN1; SMN2NFE2L2PRMT1MAPTLMNA | |
| SCHEMBL5164827 | 0.73 | NFE2L2 (0.44) | SMN1; SMN2NFE2L2MAPTLMNAALDH1A1 | |
| SCHEMBL18537139 | 0.73 | SMN1; SMN2 (0.44) | SMN1; SMN2NFE2L2GAAMAPTLMNA | |
| SCHEMBL11439318 | 0.71 | KDM4E (0.39) | GAAMAPTALDH1A1KDM4EHPGD | |
| SCHEMBL8898359 | 0.71 | MAPT (0.33) | SMN1; SMN2GAAMAPTLMNAALDH1A1 | |
| SCHEMBL10451316 | 0.71 | AR (0.49) | SMN1; SMN2NFE2L2ALDH1A1CA12CA1 | |
| SCHEMBL29749364 | 0.71 | AR (0.49) | SMN1; SMN2NFE2L2ALDH1A1CA12CA1 | |
| SCHEMBL2094872 | 0.71 | SMN1; SMN2 (0.45) | SMN1; SMN2NFE2L2NPC1PRMT1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 269 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11891668-B2 | Methods for generating therapeutic delivery platforms | THE UNIVERSITY OF KANSAS (US) | 2024-02-06 | — | — | US | claimed |
| US-20130052690-A1 | PCR PRIMER AND METHOD FOR REDUCING NON-SPECIFIC NUCLEIC ACID AMPLIFICATION USING A PHOTOLABILE PROTECTING GROUP | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2013-02-28 | — | — | US | claimed |
| US-6747143-B2 | PREPARATION OF SEQUENCES ON SUBSTRATE; OBTAIN SUBSTRATE, DEPOSIT ON PLATE SURFACE, INCUBATE WITH ACTIVATOR, REMOVE PROTECTIVE GROUPS, RECOVER BIOPOLYMER | AFFYMETRIX, INC. | 2004-06-08 | — | — | US | claimed |
| US-6660234-B2 | Generation of preferential nucleotide sequences on preferential substrate; obtain substrate, expose to activator, remove terminal groups, recover biopolymer | AFFYMETRIX, INC. | 2003-12-09 | — | — | US | claimed |
| US-12037414-B2 | Processes for preparing pharmaceutically relevant peptides | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-20240158400-A1 | SYNTHESIS OF A BRUTON'S TYROSINE KINASE INHIBITOR | PHARMACYCLICS LLC (US) | 2024-05-16 | — | — | US | disclosed |
| US-20240108740-A1 | THERAPEUTIC COMPOSITIONS INCLUDING SPN10 AND USES THEREOF | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-04-04 | — | — | US | disclosed |
| US-20240092799-A1 | MNK INHIBITORS | HEPAGENE THERAPEUTICS HK LTD (CN) | 2024-03-21 | — | — | US | disclosed |
| US-11891668-B2 | Methods for generating therapeutic delivery platforms | THE UNIVERSITY OF KANSAS (US) | 2024-02-06 | — | — | US | disclosed |
| US-20230032473-A1 | NAD(H) NANOPARTICLES AND METHODS OF USE | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2023-02-02 | — | — | US | disclosed |
| US-11548913-B2 | Therapeutic compositions including peptides and uses thereof | STEALTH BIOTHERAPEUTICS INC. (US) | 2023-01-10 | — | — | US | disclosed |
| US-20220220152-A1 | BIVALENT ANTAGONISTS OF INHIBITORS OF APOPTOSIS PROTEINS | Hepagene Therapeutics (HK) Limited (HK) | 2022-07-14 | — | — | US | disclosed |
| EP-0619321-A1 | Very large scale immobilized peptide synthesis | AFFYMAX TECHNOLOGIES N.V. (AN) | 1994-10-12 | — | — | EP | disclosed |
| EP-0476014-B1 | VERY LARGE SCALE IMMOBILIZED POLYMER SYNTHESIS | AFFYMAX TECH NV (AN) | 1994-08-31 | — | — | EP | disclosed |
| US-5252743-A | Using cage binding compound | AFFYMAX TECHNOLOGIES N.V. (NL) | 1993-10-12 | — | — | US | disclosed |
| EP-0513543-A1 | Derivatives of amidinophenylalanine, procedure for their preparation, their utilisation and anticoagulant compositions comprising them. | BEHRINGWERKE Aktiengesellschaft (DE) | 1992-11-19 | — | — | EP | disclosed |
| US-5143854-A | LARGE SCALE PHOTOLITHOGRAPHIC SOLID PHASE SYNTHESIS OF POLYPEPTIDES AND RECEPTOR BINDING SCREENING THEREOF | AFFYMAX TECHNOLOGIES N.V. (AN) | 1992-09-01 | — | — | US | disclosed |
| WO-1992010587-A1 | SEQUENCING OF SURFACE IMMOBILIZED POLYMERS UTILIZING MICROFLUORESCENCE DETECTION | AFFYMAX TECHNOLOGIES N.V. (AN) | 1992-06-25 | — | — | WO | disclosed |
| EP-0476014-A1 | VERY LARGE SCALE IMMOBILIZED POLYMER SYNTHESIS. | AFFYMAX TECH NV (NL) | 1992-03-25 | — | — | EP | disclosed |
| WO-1990015070-A1 | VERY LARGE SCALE IMMOBILIZED PEPTIDE SYNTHESIS | AFFYMAX TECHNOLOGIES N.V. (AN) | 1990-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130052690-A1 | PCR PRIMER AND METHOD FOR REDUCING NON-SPECIFIC NUCLEIC ACID AMPLIFICATION USING A PHOTOLABILE PROTECTING GROUP | POLL, POLRMT, POLN | SMN1; SMN2 3252/4885NFE2L2 2074/4885NPC1 3926/4885 |
| US-20240092799-A1 | MNK INHIBITORS | MKNK1, MATK, NEK1 | SMN1; SMN2 360/4885NFE2L2 1444/4885NPC1 1571/4885 |
| US-11891668-B2 | Methods for generating therapeutic delivery platforms | EXOSC4, EXOSC5, EXOSC9 | SMN1; SMN2 1755/4885NFE2L2 2883/4885NPC1 2448/4885 |
| US-12037414-B2 | Processes for preparing pharmaceutically relevant peptides | ADM2, VIP, PEPD | SMN1; SMN2 1676/4885NFE2L2 4394/4885NPC1 3742/4885 |
| US-20240158400-A1 | SYNTHESIS OF A BRUTON'S TYROSINE KINASE INHIBITOR | BTK, ABL1, LYN | SMN1; SMN2 3705/4885NFE2L2 3397/4885NPC1 4433/4885 |
| US-11548913-B2 | Therapeutic compositions including peptides and uses thereof | VIP, IAPP, TNNI3 | SMN1; SMN2 539/4885NFE2L2 2112/4885NPC1 1865/4885 |
| US-20240108740-A1 | THERAPEUTIC COMPOSITIONS INCLUDING SPN10 AND USES THEREOF | S100A10, SPG11, TMSB10 | SMN1; SMN2 763/4885NFE2L2 3330/4885NPC1 864/4885 |
| US-20220220152-A1 | BIVALENT ANTAGONISTS OF INHIBITORS OF APOPTOSIS PROTEINS | BIRC5, BIRC2, BIRC3 | SMN1; SMN2 3421/4885NFE2L2 2722/4885NPC1 4142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.